A Phase 1 interventional study of Linagliptin/Metformin ER FDC and Linagliptin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-04.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to demonstrate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing linagliptin and metformin extended release compared to the free combination of linagliptin and metformin extended release, both under fed and fasted conditions.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER
single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER
Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER
single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
Drug: Linagliptin/Metformin ER FDC · Drug: Linagliptin · Drug: Metformin ER
Drug pages: Linagliptin · Metformin
1x Linagliptin/Metformin FDC tablet
1x Linagliptin tablet
2x Metformin ER tablets
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72)
AUC 0-72 (area under concentration-time curve of the Linagliptin in plasma from 0 to 72 hours) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Maximum Measured Concentration of Linagliptin in Plasma (Cmax)
Cmax (maximum measured concentration of Linagliptin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
AUC 0-t (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Cmax of Metformin in Plasma
Cmax (maximum measured concentration of the Metformin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)
AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Linagliptin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
AUC0-inf of Metformin in Plasma
AUC0-inf(area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h,1h 30min, 2h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h,34h, 48h and 72h after drug administration
The study is conducted in two parts: Part 1 of the study was conducted in fasting conditions. Part 2 of the study was conducted in fed conditions.
| Milestone | FDC 1000 Fast/ L+M 1000 Fast | L+M1000 Fast/ FDC1000 Fast | FDC1000 Fed/L+M1000 Fed | L+M1000 Fed/ FDC1000 Fed |
|---|---|---|---|---|
| Started | 26 | 26 | 8 | 8 |
| Completed | 26 | 26 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | FDC 1000 Fast/ L+M 1000 Fast | L+M1000 Fast/ FDC1000 Fast | FDC1000 Fed/L+M1000 Fed | L+M1000 Fed/ FDC1000 Fed |
|---|---|---|---|---|
| Started | 26 | 26 | 8 | 8 |
| Completed | 26 | 26 | 7 | 6 |
| Not completed | 0 | 0 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Milestone | FDC 1000 Fast/ L+M 1000 Fast | L+M1000 Fast/ FDC1000 Fast | FDC1000 Fed/L+M1000 Fed | L+M1000 Fed/ FDC1000 Fed |
|---|---|---|---|---|
| Started | 26 | 26 | 7 | 6 |
| Completed | 26 | 26 | 7 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
AUC 0-72 (area under concentration-time curve of the Linagliptin in plasma from 0 to 72 hours) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
| nmol*h/L | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours (AUC0-72) | 286.639 ± 11.8 | 287.696 ± 11.8 | 234.052 ± 9.2 | 221.644 ± 9.2 |
Cmax (maximum measured concentration of Linagliptin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
| nmol/L | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| Maximum Measured Concentration of Linagliptin in Plasma (Cmax) | 8.826 ± 27.1 | 9.540 ± 27.1 | 5.791 ± 6.1 | 5.689 ± 6.1 |
AUC 0-t (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
| ng∙h/mL | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) | 7146.61 ± 22.2 | 7146.00 ± 22.2 | 11326.12 ± 7.1 | 10980.17 ± 7.1 |
Cmax (maximum measured concentration of the Metformin in plasma) The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
| ng/mL | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| Cmax of Metformin in Plasma | 925.709 ± 23.4 | 923.543 ± 23.4 | 947.445 ± 5.9 | 937.685 ± 5.9 |
AUC0-inf (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Linagliptin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
| nmol*h/L | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf) | 461.306 ± 14.3 | 460.009 ± 14.3 | 397.945 ± 32.4 | 387.424 ± 32.4 |
AUC0-inf(area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin. The values for geometric mean and geometric coefficient of variation (gCV) are actually adjusted geometric means and adjusted intra-individual gCVs, respectively.
| ng∙h/mL | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| AUC0-inf of Metformin in Plasma | 7607.75 ± 21.7 | 7540.21 ± 21.7 | 15047.37 ± 7.2 | 14773.59 ± 7.2 |
Collected over From the first drug administration for at least 7 days after the last drug administration, up to 49 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| L+M 1000 Fasted | — | 0/52 (0%) | 4/52 (7.7%) |
| FDC 1000 Fasted | — | 0/52 (0%) | 9/52 (17.3%) |
| L+M 1000 Fed | — | 2/15 (13.3%) | 4/15 (26.7%) |
| FDC 1000 Fed | — | 0/14 (0%) | 4/14 (28.6%) |
| Event | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| Acetabulum fractureInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| Bone contusionInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| ConcussionInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| FallInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| Muscle contusionInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/52 | 0/52 | 1/15 | 0/14 |
| Event | L+M 1000 Fasted | FDC 1000 Fasted | L+M 1000 Fed | FDC 1000 Fed |
|---|---|---|---|---|
| HeadacheNervous system disorders | 3/52 | 5/52 | 2/15 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 1/52 | 4/52 | 0/15 | 1/14 |
| FatigueGeneral disorders | 0/52 | 0/52 | 0/15 | 1/14 |
| RhinitisInfections and infestations | 0/52 | 2/52 | 0/15 | 1/14 |
| Decreased appetiteMetabolism and nutrition disorders | 0/52 | 0/52 | 0/15 | 1/14 |
| RashSkin and subcutaneous tissue disorders | 0/52 | 0/52 | 0/15 | 1/14 |
| VertigoEar and labyrinth disorders | 0/52 | 0/52 | 1/15 | 0/14 |
| Abdominal discomfortGastrointestinal disorders | 0/52 | 0/52 | 1/15 | 0/14 |
| DizzinessNervous system disorders | 0/52 | 2/52 | 1/15 | 0/14 |
Treated set: All randomised subjects who received 1 dose of trial medication were included in the treated set.
| Age, Continuous(years) | FDC 1000 Fast or L+M 1000 Fast | FDC 1000 Fed or L+M 1000 Fed | Total |
|---|---|---|---|
| Mean | 34.7 ± 10.4 | 36.1 ± 11.9 | 35.0 ± 10.7 |
| Sex: Female, Male(Participants) | FDC 1000 Fast or L+M 1000 Fast | FDC 1000 Fed or L+M 1000 Fed | Total |
|---|---|---|---|
| Female | 29 | 10 | 39 |
| Male | 23 | 6 | 29 |
The record gives a start of Apr 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Metformin